These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 21948492)
1. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. López-Siguero J; Borrás Pérez MV; Balser S; Khan-Boluki J Adv Ther; 2011 Oct; 28(10):879-93. PubMed ID: 21948492 [TBL] [Abstract][Full Text] [Related]
2. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]. Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383 [TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study. Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand. Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422 [TBL] [Abstract][Full Text] [Related]
6. Acromegalic features in growth hormone (GH)-deficient patients after long-term GH therapy. Carvalho LR; de Faria ME; Osorio MG; Estefan V; Jorge AA; Arnhold IJ; Mendonca BB Clin Endocrinol (Oxf); 2003 Dec; 59(6):788-92. PubMed ID: 14974923 [TBL] [Abstract][Full Text] [Related]
7. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children? Lanes R; Jakubowicz S J Pediatr; 2002 Nov; 141(5):606-10. PubMed ID: 12410186 [TBL] [Abstract][Full Text] [Related]
8. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial. Arends NJ; Boonstra VH; Mulder PG; Odink RJ; Stokvis-Brantsma WH; Rongen-Westerlaken C; Mulder JC; Delemarre-Van de Waal H; Reeser HM; Jansen M; Waelkens JJ; Hokken-Koelega AC Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I (IGF-I), insulin-like growth factor binding proteins (IGFBP) and insulin-like growth factor type I receptor in children with various status of chronic renal failure. Houang M; Cabrol S; Perin L; Ducos B; Bensman A; Le Bouc Y Growth Horm IGF Res; 2000 Dec; 10(6):332-41. PubMed ID: 11161964 [TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913 [TBL] [Abstract][Full Text] [Related]
11. Measurement of IGF-1, IGFBP-3 and free IGF-1 levels by ELISA in growth hormone (GH) deficient children before and after GH replacement. Wacharasindhu S; Aroonparkmongkol S; Srivuthana S Asian Pac J Allergy Immunol; 2002 Sep; 20(3):155-60. PubMed ID: 12587838 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy. Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children. Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841 [TBL] [Abstract][Full Text] [Related]
15. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age. Schwarz HP; Walczak M; Birkholz-Walerzak D; Szalecki M; Nanu M; Woehling H; Schuck E Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776 [TBL] [Abstract][Full Text] [Related]
16. Impact of overweight on effectiveness of treatment with human growth hormone in growth hormone deficient children: analysis of German KIGS data. Reinehr T; Bechtold-Dalla Pozza S; Bettendorf M; Doerr HG; Gohlke B; Hauffa BP; Kaspers S; Land C; Mehls O; Schwab KO; Stahnke N; Ranke MB; Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):544-8. PubMed ID: 22006181 [TBL] [Abstract][Full Text] [Related]
17. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial. Borrás Pérez V; López-Siguero JP; Martínez G; Corripio R; Fernández JM; Labarta JI; Ferrer M; Cabrinety N; Prieto P; Ramón-Krauel M; Bosch J; Espino R; Palla Garcia M; Rebollo FJ Adv Ther; 2015 Feb; 32(2):148-56. PubMed ID: 25667132 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Peterkova V; Arslanoglu I; Bolshova-Zubkovskaya E; Romer T; Zdravkovic D; Kratzsch J; Ji HJ; Savoy C; Saenger P Horm Res; 2007; 68(6):288-93. PubMed ID: 17627092 [TBL] [Abstract][Full Text] [Related]
19. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD). Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]